Aspirin resistance and diabetes mellitus

Diabetologia

Volumn 51, Issue 3, 2008, Pages 385-390

  Ajjan, R ^a   Storey, R F ^b   Grant, P J ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Aspirin resistance; Clotting factors; Diabetes mellitus; Platelets

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

BLOOD CLOTTING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DRUG MECHANISM; DRUG RESISTANCE; HEART PROTECTION; HUMAN; NOTE; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT FAILURE;

ASPIRIN; BLOOD PLATELETS; DIABETES COMPLICATIONS; DIABETIC ANGIOPATHIES; DRUG RESISTANCE; HUMANS; PLATELET AGGREGATION INHIBITORS; VASCULAR DISEASES;

EID: 39049101880     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00125-007-0898-3     Document Type: Note

References (43)

1. Cubbon RM, Wheatcroft SB, Grant PJ et al (2007) Temporal trends in mortality of patients with diabetes mellitus suffering acute myocardial infarction: a comparison of over 3000 patients between 1995 and 2003. Eur Heart J 28:540-545
2. Nicolucci A, De Berardis G, Sacco M, Tognoni G (2007) AHA/ADA vs ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. Eur Heart J 28:1925-1927
3. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 324:71-86
4. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, Nicolucci A (2003) Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes Care 26:3264-3272
5. Mason PJ, Jacobs AK, Freedman JE (2005) Aspirin resistance and atherothrombotic disease. J Am Coll Cardiol 46:986-993
6. Sanderson S, Emery J, Baglin T, Kinmonth AL (2005) Narrative review: aspirin resistance and its clinical implications. Ann Intern Med 142:370-380
7. 2-terminal serine of prostaglandin synthetase by aspirin. J Biol Chem 253:3782-3784
8. Patrono C, Ciabattoni G, Patrignani P et al (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72:1177-1184
9. Kuster LJ, Frölich JC (1986) Platelet aggregation and thromboxane release induced by arachidonic acid, collagen, ADP and platelet-activating factor following low dose acetylsalicylic acid in man. Prostaglandins 32:415-423
10. Willerson JT, Golino P, Eidt J, Campbell WB, Buja LM (1989) Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications. Circulation 80:198-205
11. Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT (1981) Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 304:685-691
12. 2: function and pharmacological regulation. Biochem Pharmacol 36:2429-2436
13. Barnes MJ, Knight CG, Farndale RW (1998) The collagen-platelet interaction. Curr Opin Hematol 5:314-320
14. Lages B, Weiss HJ (1981) Dependence of human platelet functional responses on divalent cations: aggregation and secretion in heparin- and hirudin-anticoagulated platelet-rich plasma and the effects of chelating agents. Thromb Haemost 45:173-179
15. 12 receptor. Curr Pharm Des 12:1255-1259
16. Fatah K, Silveira A, Tornvall P, Karpe F, Blomback M, Hamsten A (1996) Proneness to formation of tight and rigid fibrin gel structures in men with myocardial infarction at a young age. Thromb Haemost 76:535-540
17. Collet JP, Park D, Lesty C et al (2000) Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc Biol 20:1354-1361
18. He S, Blomback M, Yoo G, Sinha R, Henschen-Edman AH (2001) Modified clotting properties of fibrinogen in the presence of acetylsalicylic acid in a purified system. Ann N Y Acad Sci 936:531-535
19. Antovic A, Perneby C, Ekman GJ et al (2005) Marked increase of fibrin gel permeability with very low dose ASA treatment. Thromb Res 116:509-517
20. Williams S, Fatah K, Hjemdahl P, Blomback M (1998) Better increase in fibrin gel porosity by low dose than intermediate dose acetylsalicylic acid. Eur Heart J 19:1666-1672
21. Pinckard RN, Hawkins D, Farr RS (1968) In vitro acetylation of plasma proteins, enzymes and DNA by aspirin. Nature 219:68-69
22. Kessels H, Beguin S, Andree H, Hemker HC (1994) Measurement of thrombin generation in whole blood-the effect of heparin and aspirin. Thromb Haemost 72:78-83
23. Undas A, Sydor WJ, Brummel K, Musial J, Mann KG, Szczeklik A (2003) Aspirin alters the cardioprotective effects of the factor XIII Val34Leu polymorphism. Circulation 107:17-20
24. Fateh-Moghadam S, Plockinger U, Cabeza N et al (2005) Prevalence of aspirin resistance in patients with type 2 diabetes. Acta Diabetol 42:99-103
25. Mehta SS, Silver RJ, Aaronson A, Abrahamson M, Goldfine AB (2006) Comparison of aspirin resistance in type 1 versus type 2 diabetes mellitus. Am J Cardiol 97:567-570
26. Fontana P, Nolli S, Reber G, de Moerloose P (2006) Biological effects of aspirin and clopidogrel in a randomized cross-over study in 96 healthy volunteers. J Thromb Haemost 4:813-819
27. Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A (2005) Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am J Cardiol 95:973-975
28. Ohmori T, Yatomi Y, Nonaka T et al (2006) Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 4:1271-1278
29. DiMinno G, Silver MJ, Cerbone AM, Murphy S (1986) Trial of repeated low-dose aspirin in diabetic angiopathy. Blood 68:886-891
30. Ajjan R, Grant PJ (2006) Coagulation and atherothrombotic disease. Atherosclerosis 186:240-259
31. Dunn EJ, Philippou H, Ariens R, Grant PJ (2006) Molecular mechanisms involved in the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. Diabetologia 49:1071-1080
32. Rendell M, Nierenberg J, Brannan C et al (1986) Inhibition of glycation of albumin and hemoglobin by acetylation in vitro and in vivo. J Lab Clin Med 108:286-293
33. Swamy-Mruthinti S, Carter AL (1999) Acetyl-l-carnitine decreases glycation of lens proteins: in vitro studies. Exp Eye Res 69:109-115
34. Watala C, Boncler M, Gresner P (2005) Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacol Rep 57(Suppl):42-58
35. Watala C, Pluta J, Golanski J et al (2005) Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med 83:148-158
36. Watala C, Ulicna O, Golanski J et al (2006) High glucose contributes to aspirin insensitivity in streptozotocin-diabetic rats: a multiparametric aggregation study. Blood Coagul Fibrinolysis 17:113-124
37. Watala C, Golanski J, Pluta J et al (2004) Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 113:101-113
38. Takahashi S, Ushida M, Komine R et al (2007) Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin. Thromb Res 119:517-524
39. Gum PA, Kottke-Marchant K, Poggio ED et al (2001) Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol 88:230-235
40. Early Treatment Diabetic Retinopathy Study Investigators (1992) Aspirin effects on mortality and morbidity in patients with diabetes mellitus. ETDRS report 14. JAMA 268:1292-1300
41. Evangelista V, Totani L, Rotondo S et al (2005) Prevention of cardiovascular disease in type 2 diabetes: how to improve the clinical efficacy of aspirin. Thromb Haemost 93:8-16
42. Bhatt DL, Marso SP, Hirsch AT, Ringleb PA, Hacke W, Topol EJ (2002) Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 90:625-628
43. Laine L (2006) Gastrointestinal bleeding with low dose aspirin-what's the risk? Aliment Pharmacol Ther 24:897-908